Clarity Pharmaceuticals Ltd. (AU:CU6)
ASX:CU6
CU6 Stock Chart & Stats
AU$3.10
-AU$0.24(-5.69%)
At close: 4:00 PM EST
AU$3.10
-AU$0.24(-5.69%)
Day’s Range― - ―
52-Week RangeAU$1.43 - AU$5.87
Previous CloseN/A
Volume1.66M
Average Volume (3M)3.27M
Market Cap
AU$1.15B
Enterprise ValueAU$953.81M
Total Cash (Recent Filing)AU$226.25M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta2.50
Next Earnings
Aug 26, 2026EPS Estimate
-0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.15
Shares Outstanding372,258,100
10 Day Avg. Volume4,406,737
30 Day Avg. Volume3,266,690
Financial Highlights & Ratios
PEG Ratio-0.37
Price to Book (P/B)8.84
Price to Sales (P/S)84.33
P/FCF Ratio-14.52
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$7.75Price Target Upside150.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.28
Revenue Forecast (FY)AU$6.55M
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetZero reported debt materially reduces financial fragility for a cash-burning biotech. It lowers interest burden and refinancing risk, preserving flexibility to fund clinical programs via equity or partnerships, and gives management optionality in structuring future financing or collaborations.
Clinical-stage Theranostics FocusA focused, clinical-stage pipeline in targeted oncology (copper-based theranostics) is a durable strategic strength: specialized IP, scientific know-how and regulatory paths create high barriers to entry and attractive partnering/licensing opportunities if clinical data validate efficacy.
High Gross Margin ProfileNear-100% gross margins reflect the inherent economics of radiopharmaceutical products and suggest very high incremental profitability once commercialized. If clinical programs succeed, this structural margin profile supports rapid conversion to positive operating leverage despite elevated fixed R&D and G&A.
Bears Say
Widening Net LossesPersistent and widening net losses erode shareholder value and signal that operating costs are outpacing revenue growth. Over months, continuous losses necessitate funding rounds, constrain reinvestment choices, and increase execution risk for clinical development timelines and commercial preparation.
Consistent Negative Cash FlowRepeated negative operating and free cash flow, and a rising cash outflow in 2025, indicate reliance on external financing. Over a multi-month horizon this weak cash generation threatens program continuity without dilution or partnerships, making long-term planning and hiring harder.
Declining Equity And Funding RiskA falling equity base reflects accumulated losses and past financing/dilution. This weakens the balance-sheet buffer, increases the likelihood of dilutive future raises, and raises execution risk for multi-stage clinical programs as investor appetite and partner terms may be affected.
Clarity Pharmaceuticals Ltd. News
CU6 FAQ
What was Clarity Pharmaceuticals Ltd.’s price range in the past 12 months?
Clarity Pharmaceuticals Ltd. lowest share price was AU$1.43 and its highest was AU$5.87 in the past 12 months.
What is Clarity Pharmaceuticals Ltd.’s market cap?
Clarity Pharmaceuticals Ltd.’s market cap is AU$1.15B.
When is Clarity Pharmaceuticals Ltd.’s upcoming earnings report date?
Clarity Pharmaceuticals Ltd.’s upcoming earnings report date is Aug 26, 2026 which is in 147 days.
How were Clarity Pharmaceuticals Ltd.’s earnings last quarter?
Clarity Pharmaceuticals Ltd. released its earnings results on Feb 26, 2026. The company reported -AU$0.153 earnings per share for the quarter, missing the consensus estimate of -AU$0.083 by -AU$0.07.
Is Clarity Pharmaceuticals Ltd. overvalued?
According to Wall Street analysts Clarity Pharmaceuticals Ltd.’s price is currently Undervalued.
Does Clarity Pharmaceuticals Ltd. pay dividends?
Clarity Pharmaceuticals Ltd. does not currently pay dividends.
What is Clarity Pharmaceuticals Ltd.’s EPS estimate?
Clarity Pharmaceuticals Ltd.’s EPS estimate is -0.16.
How many shares outstanding does Clarity Pharmaceuticals Ltd. have?
Clarity Pharmaceuticals Ltd. has 372,258,100 shares outstanding.
What happened to Clarity Pharmaceuticals Ltd.’s price movement after its last earnings report?
Clarity Pharmaceuticals Ltd. reported an EPS of -AU$0.153 in its last earnings report, missing expectations of -AU$0.083. Following the earnings report the stock price went up 0.278%.
Which hedge fund is a major shareholder of Clarity Pharmaceuticals Ltd.?
Currently, no hedge funds are holding shares in AU:CU6
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Clarity Pharmaceuticals Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$7.75 (150.00% Upside)
AU$7.75 (150.00% Upside)
Blogger Sentiment
Bullish
AU:CU6 Sentiment 90%
Sector Average 69%
Sector Average 69%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-25.03%
12-Months-Change
Fundamentals
Return on Equity
-54.37%
Trailing 12-Months
Asset Growth
-34.57%
Trailing 12-Months
Company Description
Clarity Pharmaceuticals Ltd.
Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, develops theranostic therapy and imaging products for the treatment of cancer in children and adults. Its lead product includes SARTATE, a targeted theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express somatostatin receptor 2. The company is also developing SAR-Bombesin, a pan cancer theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express gastrin releasing peptide receptor; and SAR-bisPSMA, a theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express prostate specific membrane antigen. The company has collaboration with GU Research Network for an investigator initiated Trial X-Calibur, using 64Cu-SAR-bisPSMA in known or suspected prostate cancer. Clarity Pharmaceuticals Ltd was incorporated in 2010 and is based in Sydney, Australia.
CU6 Stock 12 Month Forecast
Average Price Target
AU$7.75
▲(150.00% Upside)
Technical Analysis
Clinuvel Pharmaceuticals
―
Immutep Ltd
―
Telix Pharmaceuticals
―
PYC Therapeutics Limited
―
Botanix Pharmaceuticals Limited
―
Options Prices
Currently, No data available
---